Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Celldex Therapeutics (NQ: CLDX )

36.85 +0.53 (+1.46%)
Streaming Delayed Price Updated: 11:40 AM EDT, May 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Celldex Therapeutics

< Previous 1 2 Next >
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Inc. (NASDAQ: CLDX) Highlighted for Surprising Price Action
Via Investor Brand Network
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Announces Pricing of Public Offering of Common Stock
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Prurigo Nodularis at 12th World Congress on Itch (WCI) 2023
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics to Present at Cantor Global Healthcare Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Announces Upcoming Barzolvolimab Presentations at EAACI 2023
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics to Present at Jefferies Healthcare Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Announces First Patient Dosed in Phase 1 Study of CDX-585 in Patients with Advanced Malignancies
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622 at IMMUNOLOGY2023™
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.